Related Experiment Video
Updated: Jun 24, 2025
High-resolution Functional Magnetic Resonance Imaging Methods for Human Midbrain
Published on: May 10, 2012
SCOUT® Localization Using MRI Guidance: Initial Experience
Brittany Z Dashevsky1, Pamela Yan1, Tie Liang1
1Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA.
Objective:
The Food and Drug Administration approved the MRI-compatible wireless SCOUT localization system in April 2022. The purpose of this study was to evaluate feasibility of SCOUT localization under MRI guidance. We present our initial experience adopting MRI-guided SCOUT localization and compare it to MRI-guided wire localization.
Methods:
Electronic medical records and imaging were retrospectively reviewed for all patients who underwent MRI-guided SCOUT or wire localization at our institution between October 2022 and July 2023. Statistical analysis was performed using 2-sample proportion and Wilcoxon rank-sum tests.
Results:
There were 14 MRI-guided SCOUT and 23 MRI-guided wire localization cases during the study period. All SCOUTs were placed without complication and were considered to be in adequate proximity to the target. There was no significant difference in complication rate (P = .25) or days lapsed from MRI-detected abnormality to surgery (P = .82) between SCOUT and wire cases. SCOUT was placed at time of biopsy for 71% (10/14) of cases. 57% (8/14) of SCOUT cases were used for breast conservation surgery (BCS) compared to 100% (23/23) of wire cases (P <.01), with all 6 SCOUTs not used for BCS placed at time of biopsy.
Conclusion:
MRI-guided SCOUT localization is feasible and offers an alternative to MRI-guided wire localization, with no SCOUT complications reported. SCOUT placement at time of biopsy obviates the need for an additional procedure, but predicting appropriateness is challenging, with 60% (6/10) of SCOUTs placed at time of MRI-guided biopsy not used for subsequent localization surgery.
Insights
MRI-guided SCOUT localization is a feasible alternative to wire localization, with no reported complications. While it can be performed during biopsy, predicting its use in breast conservation surgery remains challenging.
Area of Science:
- Radiology
- Surgical Oncology
- Medical Devices
Background:
- The MRI-compatible wireless SCOUT localization system was approved by the FDA in April 2022.
- MRI-guided localization is crucial for precise surgical targeting of abnormalities detected on MRI.
Purpose of the Study:
- To evaluate the feasibility of MRI-guided SCOUT localization.
- To compare the outcomes of MRI-guided SCOUT localization with traditional MRI-guided wire localization.
Main Methods:
- Retrospective review of electronic medical records and imaging for patients undergoing MRI-guided SCOUT or wire localization between October 2022 and July 2023.
- Statistical analysis using 2-sample proportion and Wilcoxon rank-sum tests to compare complication rates and time to surgery.
Main Results:
- 14 MRI-guided SCOUT and 23 MRI-guided wire localization cases were analyzed.
- All SCOUT placements were uncomplicated and adequately positioned.
- No significant differences in complication rates or time from detection to surgery were observed between SCOUT and wire localization.
Conclusions:
- MRI-guided SCOUT localization is a feasible alternative to wire localization with no reported complications.
- While SCOUT placement during biopsy can eliminate an extra procedure, predicting its suitability for subsequent breast conservation surgery requires further investigation, as 60% of those placed at biopsy were not used for surgery.
